Shay Capital’s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share DNA.WS Stock Holding History

Shay Capital’s Portfolio DNA.WS Stock Details DNA.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-127,596	Closed	-$13.4K	–	489
2023 Q4	$13.4K	Buy	127,596 +12,810	+11%	+$1.89K	﹤0.01%	265
2023 Q3	$25.8K	Buy	114,786 +20,164	+21%	+$5.42K	﹤0.01%	325
2023 Q2	$24.8K	Buy	94,622 +2,547	+3%	+$496	﹤0.01%	375
2023 Q1	$16.6K	Buy	92,075 +4,650	+5%	+$1.06K	﹤0.01%	409
2022 Q4	$17.5K	Buy	+87,425	New	+$37.5K	0.01%	259
2022 Q3	–	Sell	-54,617	Closed	-$29K	–	542
2022 Q2	$29K	Buy	+54,617	New	+$34.6K	0.01%	385

Other funds holding DNA.WS

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JRCM

Jones Road Capital Management New York $55.3M AUM 29.97% 1-Year Est. Return

Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return

Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return

Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Shay Capital's DNA.WS Position: Q1 2024 in Review

Shay Capital sold out of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) in Q1 2024, closing a stake of 127,596 shares — an estimated $13.4K sold.

Shay Capital first reported a position in DNA.WS in Q2 2022 and held it in 6 quarters. The position peaked at $29K in Q2 2022. 28 funds tracked by Wall St. Rank hold DNA.WS as of Q1 2024.

Shay Capital reported no remaining Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position as of Q1 2024 after selling out during the quarter.
Shay Capital sold 127,596 Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share shares in Q1 2024, an estimated $13.4K.
Shay Capital first reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in Q2 2022 and held it in 6 quarters.
Shay Capital's Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position peaked at $29K in Q2 2022.
28 funds tracked by Wall St. Rank held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share as of Q1 2024.

Based on Shay Capital's 13F filing for Q1 2024, filed 15 May 2024.